Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Acq. announced
Consulting agrmnt
Appointed director
|
|
CORNERSTONE THERAPEUTICS INC (CRTX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/19/2012 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/19/2012 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/07/2012 |
8-K/A
| Financial Statements and Exhibits|
Docs:
|
"Consent of McGladrey LLP",
"Consent of PricewaterhouseCoopers LLP",
"Audited consolidated financial statements of EKR Holdings, Inc. as of December 31, 2011 and 2010 and for each of the three years ended December 31, 2011, 2010 and 2009",
"Unaudited consolidated financial statements of EKR Holdings, Inc. as of March 31, 2012 and December 31, 2011 and for the three months ended March 31, 2012 and 2011",
"Unaudited pro forma combined balance sheet and statement of operations of the Company as of and for the three months ended March 31, 2012 and the unaudited pro forma combined statement of operations of the Company for the year ended December 31, 2011" |
|
| 03/16/2012 |
8-K/A
| Form 8-K - Current report [amend] |
| 01/12/2012 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/05/2010 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/11/2009 |
8-K/A
| Financial Statements and Exhibits|
Docs:
|
"Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results Cary, N.C., August 11, 2009 - Cornerstone Therapeutics Inc. , a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today reported financial results for the three and six months ended June 30, 2009. Recent Highlights: § Second quarter net revenues increase $10.9 million to $25.0 million, or 78%, compared to 2008 § Cash balance improves to $15.5 million at June 30, 2009 from $9.3 million at December 31, 2008 § $70 million strategic transaction with Chiesi Farmaceutici S.p.A. closes, adding a further $14.1 million in cash, net of $1.4 million of transaction-related costs that were expensed in the second..." |
|
| 06/26/2009 |
8-K/A
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 01/15/2009 |
8-K/A
| Form 8-K/A -- Current report [amend] |
| 11/14/2008 |
8-K/A
| Form 8-K/A -- Current report [amend] |
| 04/02/2008 |
8-K/A
| Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ... |
|
|